• Home

  • HEALTH CARE

  • HEALTHY LIFESTYLE

  • HYGIENE

  • COSMETICS

  • FOR HIM

  • PREGNANCY AND MOTHERHOOD

  • CHILD

  • Lira solution for injection 1000 mg/4 ml, 4ml x 10 ampoules — Made in Ukraine — Free Delivery


    Brand: Farmak
    Product Code: Lira
    Availability: In Stock
    $36.89
    Add to Cart

    Pharmacological properties

    Pharmacodynamics. Citicoline stimulates the biosynthesis of structural phospholipids of neuronal membranes, which is confirmed by the data of magnetic resonance spectroscopy. Citicoline improves the functioning of membrane mechanisms such as ion pumps and receptors, without the regulation of which it is impossible for the normal conduction of nerve impulses. due to the stabilizing effect on the membrane of neurons, citicoline exhibits decongestant properties that contribute to the reabsorption of cerebral edema.
    Clinical studies have shown that citicoline inhibits the activation of certain phospholipases (A1, A2, C and D), decreasing the formation of free radicals, preventing the destruction of membrane systems, and preserving antioxidant defense systems such as glutathione.
    Citicoline preserves neuronal energy stores, inhibits apoptosis, which improves cholinergic transmission.
    It has been experimentally proven that citicoline also has a prophylactic neuroprotective effect in focal cerebral ischemia.
    Clinical studies have shown that citicoline significantly increases the indicators of functional recovery in patients with acute cerebrovascular accident, which coincides with a slowdown in the growth of ischemic brain damage according to neuroimaging data. In patients with traumatic brain injury, citicoline accelerates recovery and reduces the duration and intensity of post-traumatic stress disorder.
    Citicoline improves the level of attention and consciousness, helps to reduce the manifestations of amnesia, cognitive and other neurological disorders associated with cerebral ischemia.
    Pharmacokinetics. Citicoline is well absorbed after oral, intramuscular and intravenous administration. Plasma choline levels rise significantly after administration by the aforementioned routes. Absorption after oral administration is almost complete, and the bioavailability is practically the same as with intravenous administration.
    Depending on the route of administration, the preparation is metabolized in the intestine, liver to choline and cytidine. After administration, citicoline is widely distributed in the structures of the brain with the rapid incorporation of the choline fraction into structural phospholipids and cytidine fractions into cytidine nucleotides and nucleic acids. Having reached the brain, citicoline is incorporated into the cellular, cytoplasmic and mitochondrial membranes, participating in the construction of the phospholipid fraction.
    Only a small amount of the dose is excreted in urine and feces (less than 3%). Approximately 12% of the dose is excreted in expired CO2. In the excretion of the preparation in the urine, two phases are distinguished: the first phase - about 36 hours, in which the rate of excretion decreases rapidly, and the second phase, in which the rate of excretion decreases much more slowly. The same phasicity is observed during excretion with CO2: the rate of excretion of exhaled CO2 decreases rapidly after about 15 hours, then it decreases much more slowly.

    Indications

    Stroke, acute phase of cerebrovascular accidents and treatment of complications and consequences of cerebrovascular accidents; traumatic brain injury and its neurological consequences; cognitive and behavioral impairments due to chronic vascular and degenerative cerebral disorders.

    Application

    For intravenous or intramuscular injection.
    The recommended dose for adults is 500-2000 mg / day, depending on the severity of the patient's condition. The maximum daily dose is 2000 mg. In acute and urgent conditions, the maximum therapeutic effect is achieved when using the preparation in the first 24 hours.
    IV is prescribed in the form of a slow injection (within 3-5 minutes, depending on the administered dose) or drip infusion (40-60 drops per minute).
    Elderly patients do not require dose adjustment.
    The preparation is compatible with all intravenous isotonic solutions, as well as with hypertonic glucose solutions.
    This solution is intended for single use. Solution must be injected immediately after opening the ampoule. The unused solution should be destroyed.
    If necessary, treatment is continued with citicoline in the form of a solution for oral administration.

    Contraindications

    Hypersensitivity to the components of the preparation, increased tone of the parasympathetic nervous system.

    Side effects

    Adverse reactions occur very rarely (1/10 000), including isolated cases.
    Mental disorders: hallucinations.
    From the nervous system: severe headache, vertigo.
    From the side of the cardiovascular system: hypertension, arterial hypotension, tachycardia.
    From the respiratory system: shortness of breath.
    From the digestive system: nausea, vomiting, diarrhea.
    From the immune system: allergic reactions, including: rash, hyperemia, exanthema, urticaria, purpura, pruritus, angioedema, anaphylactic shock.
    General disorders: chills, reactions at the injection site.

    Special instructions

    In the case of persistent intracranial hemorrhage, a dose of 1000 mg / day and an infusion rate of 30 drops per minute should not be exceeded.
    Use during pregnancy and lactation. There is insufficient data on the use of citicoline in pregnant women. There are no data on the excretion of citicoline in breast milk and its effect on the fetus. Therefore, during pregnancy and lactation, the preparation is prescribed only when the expected benefit to the mother outweighs the potential risk to the fetus.
    Children. The experience of using the preparation in children is limited. The preparation  is used in case of emergency, when the expected benefit from the use outweighs the possible risk.
    The ability to influence the reaction rate when driving or working with other mechanisms. In some cases, some side reactions from the central nervous system can affect the ability to drive vehicles or operate machinery.

    Interactions

    Citicoline enhances the effect of levodopa. the preparation should not be administered concurrently with medicinal products containing meclofenoxate.
    Incompatibility. Do not use solvents specified in the APPLICATION section.

    Overdose

    Overdose cases are not described.

    Storage conditions

    At a temperature not exceeding 30 ° c.

    There are no reviews for this product.